Filed under: Good news, General Electric (GE), Technical Analysis, Stocks to Buy
Among the most sought after goals of medical technology research is the development of minimally invasive methods for the determination of internal disorders. An outfit in Yoqneam, Israel is a leader in the field.
Given Imaging (NASDAQ: GIVN) manufactures diagnostic products for the visualization and detection of disorders of the gastrointestinal tract. Its principal product is a wireless imaging system that features a “PillCam” video capsule that is ingested by the patient. As the pill passes through the G.I. tract, associated system electronics interpret and record the video signals it transmits. The company also offers a dissolvable capsule system that enables physicians to determine whether there are obstructions or strictures in the gastrointestinal tract. General Electric (NYSE: GE) is a major competitor.
The stock has been a steady gainer over the past two weeks, rising on analyst predictions of further product regulatory approvals
and speculation regarding the firm’s position as a takeover candidate. Also, there has been word that “PillCam” esophageal applications will be covered by National Government Services, the Medicare Part B Carrier serving more than six million individuals in New York, New Jersey, Kentucky and Indiana. Shares are advancing through a positive trading channel. The price is currently consolidating at the base of that channel, suggesting the potential for a turn back toward the top.
Brokers recommend the issue with two “buys,” one “hold” and one “sell.” Analysts expect a 34 percent average annual growth rate, through the next five years. The GIVN Sales Growth rate (19.83%) and EPS Growth rate (-0.02 to +0.09 yr/yr) compare favorably with industry, sector and S&P 500 averages. Institutional investors hold about 25 percent of the outstanding shares. Over the past 52 weeks, the stock has traded between $18.96 and $32.80. A stop-loss of $25.95 looks good here. Note that the firm is next expected to release quarterly results on, or about, November 1.
Larry Schutts is a contributing editor for Theflyonthewall.com and the Vice-President of Stockwinners.com.
Permalink | Email this | Comments











Entries (RSS)